Pasithea Therapeutics Corp. (KTTA) News
Follow Pasithea Therapeutics Corp. (KTTA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
KTTA’s PAS-004 advances Phase 1 for NF1 and MAPK-driven cancers
PAS-004 is advancing through Phase 1 trials for NF1 and MAPK-driven cancers, aiming to address major unmet needs with improved dosing and tolerability. Early data point to promising efficacy and safety, especially for NF
EQUITY | Sep 09, 2026, 05:17 PM UTC
L
Directors elected, auditors ratified in majority vote
The meeting also authorized a reverse stock split at a flexible ratio, with all proposals passing by majority vote.
EQUITY | Sep 09, 2026, 01:34 PM UTC
L
KTTA shareholders approve director elections, auditor ratification, reverse split
At a shareholder meeting, KTTA proposals including director elections, auditor ratification and a reverse stock split were approved by majority vote. No questions were raised; final results will be filed with the SEC.
REGULATION | Sep 09, 2026, 01:25 PM UTC
L
Pasithea Therapeutics to meet investors at Sept 2026 conferences
Pasithea Therapeutics will hold one-on-one investor meetings at the 12th Annual Cantor Global Healthcare Conference (September 9-11) and will present at the H.C. Wainwright 28th Annual Global Investment Conference (Septe
EQUITY | Sep 03, 2026, 08:08 PM UTC
L
KTTA: Coastlands Buys
Coastlands Capital LP buys 100,000 shares of Pasithea Therapeutics Corp.
EQUITY | Jun 22, 2026, 02:31 PM UTC